<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04745910</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0330</org_study_id>
    <secondary_id>NCI-2020-13890</secondary_id>
    <secondary_id>2020-0330</secondary_id>
    <nct_id>NCT04745910</nct_id>
  </id_info>
  <brief_title>Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome</brief_title>
  <official_title>Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies the effect of pegloticase in reducing uric acid levels in patients with&#xD;
      hyperuricemia (high blood levels of uric acid) caused by tumor lysis syndrome. Tumor lysis&#xD;
      syndrome occurs when the breakdown products of cancer cells, such as uric acid, enter the&#xD;
      blood stream. High levels of uric acid in blood may cause kidney damage and reduce kidney&#xD;
      function. The goal of this trial is to learn if pegloticase may lower uric acid levels in&#xD;
      blood when given to cancer patients with hyperuricemia caused by tumor lysis syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To collect preliminary data on the effectiveness of a single dose of pegloticase in&#xD;
      lowering serum uric acid levels to less than 6.0 mg/dl within 24 hours in patients with&#xD;
      hyperuricemia in the setting of tumor lysis syndrome.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To estimate the time to a serum uric acid reduction to &lt; 6.0 mg/dl within 24 hours after&#xD;
      administration of pegloticase in patients with hyperuricemia in the setting of tumor lysis&#xD;
      syndrome.&#xD;
&#xD;
      II. To assess the effect of pegloticase on renal function in patients with hyperuricemia in&#xD;
      the setting of tumor lysis syndrome as measured by changes in serum creatinine/estimated&#xD;
      glomerular filtration rate (eGFR) and urine output.&#xD;
&#xD;
      III. To estimate the rate of renal replacement therapy initiation for acute kidney injury&#xD;
      secondary to tumor lysis syndrome among patients treated with pegloticase.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive pegloticase intravenously (IV) over 120 minutes. Patients whose serum uric&#xD;
      acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over&#xD;
      120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two&#xD;
      doses of pegloticase receive standard of care rasburicase IV once daily (QD) for 5 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 31, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Within 24 hours of single dose of pegloticase</time_frame>
    <description>Will estimate the 24-hour response rate along with the corresponding 90% confidence interval. In addition, the report will present plots of uric acid levels across all time points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time from pegloticase infusion until serum uric acid levels drop to 6 mg/dL</measure>
    <time_frame>Up to 14 days after pegloticase administration</time_frame>
    <description>Will display results in frequency tables and plots of serum uric acid levels across time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>Up to 14 days after pegloticase administration</time_frame>
    <description>Will summarize serum creatinine and estimated glomerular filtration rate at each time point and plot these lab values across time. Finally, will calculate the rate and 90% confidence interval for the initiation of renal replacement therapy within the 14-day observation window.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serum uric acid level</measure>
    <time_frame>Up to 14 days after pegloticase administration</time_frame>
    <description>Will examine the association of baseline characteristics with serum uric acid level using the Fisher's exact test, student's t-test, paired t-test, Wilcoxon rank-sum test, or Wilcoxon signed-rank test and will employ graphical methods when useful.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Tumor Lysis Syndrome</condition>
  <arm_group>
    <arm_group_label>Treatment (pegloticase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive pegloticase IV over 120 minutes. Patients whose serum uric acid does not drop below 6 mg/dL within 24 hours receive a second dose of pegloticase IV over 120 minutes on day 2. Patients whose serum uric acid does not drop below 6 mg/dL after two doses of pegloticase receive standard of care rasburicase IV QD for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegloticase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pegloticase)</arm_group_label>
    <other_name>Des-(1-6)-(7-threonine,46-threonine,291-lysine,301-serine)uricase (EC 1.7.3.3, urate oxidase) Sus scrofa (pig) tetramer, Non Acetylated, Carbamates with alpha-carboxy-omega-methoxypoly(oxyethylene)</other_name>
    <other_name>Krystexxa</other_name>
    <other_name>Methoxypolyethylene Glycol Uricase</other_name>
    <other_name>Oxidase, Urate (Synthetic Sus scrofa variant pigks-DN subunit), homotetramer, amide with alpha-carboxy-omega-methoxypoly(oxy-1,2-ethanediyl)</other_name>
    <other_name>Polyethylene Glycol-uricase</other_name>
    <other_name>Puricase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rasburicase</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (pegloticase)</arm_group_label>
    <other_name>Elitek</other_name>
    <other_name>Recombinant Urate Oxidase</other_name>
    <other_name>SR 29142</other_name>
    <other_name>SR-29142</other_name>
    <other_name>Urate Oxidase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent prior to any study specific procedures (patient or caregiver)&#xD;
&#xD;
          -  Male or female 18 years of age or older&#xD;
&#xD;
          -  In the investigator's opinion, expected survival of at least 1 month&#xD;
&#xD;
          -  Deemed stable by the investigator&#xD;
&#xD;
          -  Serum uric acid &gt; 6 mg/dL (measured as average of 3 days prior, +/- 1 days)&#xD;
&#xD;
          -  High risk for tumor lysis syndrome based on the MD Anderson Tumor Lysis Syndrome (TLS)&#xD;
             risk score&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability or refusal to give informed consent (patient or caregiver)&#xD;
&#xD;
          -  Subject unwilling to take study medication&#xD;
&#xD;
          -  Known allergy to uricase&#xD;
&#xD;
          -  Pregnant&#xD;
&#xD;
          -  Breastfeeding&#xD;
&#xD;
          -  Known glucose-6-phosphate dehydrogenase (G6PD) deficiency or transfusion in last 7&#xD;
             days (as this interferes with G6PD test)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sreedhar Mandayam</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Sreedhar Mandayam</last_name>
      <phone>713-745-8597</phone>
      <email>samandayam@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sreedhar Mandayam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 3, 2021</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 9, 2021</study_first_posted>
  <last_update_submitted>February 4, 2021</last_update_submitted>
  <last_update_submitted_qc>February 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Tumor Lysis Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

